SCIEX, QPS Holdings Collaborate
News Apr 06, 2016
SCIEX and QPS Holdings announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.
Pharmaceutical and biopharmaceutical therapeutic portfolios have evolved from 10% large molecule therapies a little over a decade ago, to now nearly 50% of the entire pipeline. As organizations transition to biologics, new challenges arise for scientists characterizing and quantifying large molecules such as peptides, proteins, monoclonal antibodies, oligonucleotides, and antibody drug conjugates in complex biological matrices. SCIEX identified the challenges of quantifying protein biologics, and developed the BioBA solution to optimize robust, reproducible and sensitive quantification methods for proteins.
The comprehensive BioBA solution includes ready-to-use sample preparation kits, a fully automated liquid sample handler, a robust LC component with outstanding resolution, and a sensitive QTRAP® MS System with software for performing bioanalytical studies designed to support CFR 21 part 11 compliance. All this is supported by SCIEX's world-class expertise in biologics bioanalysis, while offering a rich repository of proven methods for many well-known biologics.
"Pharmaceutical and biopharmaceutical companies rely on CROs for productivity and robustness in bioanalytical analysis," said Farzana Azam, Senior Director of Pharma/CRO Business at SCIEX. "The integrated BioBA solution enables scientists transitioning from traditional small molecule bioanalysis to biologics, to generate robust, reproducible and high-quality data. BioBA empowers scientists to turn the complexities of biologics bioanalysis into a simple process for both experts and non-experts, making the transition from small to large molecules easier than you think."
"As a full CRO, we must meet the needs of the large pharmaceutical and biopharmaceutical industry in a productive manner with solutions that offer robustness and confidence," said John Kolman, Executive Director and Head of Translational Medicine at QPS. "SCIEX’s BioBA solution is all about simplicity, standardization and efficiency, which offers QPS a running start towards achieving that right answer faster when it comes to large molecule bioanalysis."
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.